Advertisement

Massachusetts life sciences companies are increasingly attracting the attention of Japanese firms. The sale of Marlborough-based Sepracor Inc. to Japanese drug maker Dainippon Sumitomo Pharma will be completed this quarter, marking the second Japanese purchase of a large local biotechnology company, following the acquisition of Millennium Pharmaceuticals by Takeda Pharmaceuticals in 2008.

“One of the reasons that we’re seeing an increase of activity here is that 10 or 15 years ago, there weren’t as many commercial-stage companies locally,” said Mark Iwicki, Sepracor’s president and chief operating officer.

SOURCE

Advertisement
Advertisement